To investigate whether DC-SIGN is involved in CRC progression, two DC-SIGN shRNAs (DC-SIGN shRNAs 1 and 2) were designed to silence DC-SIGN expression via lentivector transduction (Supplementary Fig. S3a, b), both of which efficiently inhibited DC-SIGN expression in LoVo and HCT116 cells (Supplementary Fig. S3c). Here, CD209 is linked to colorectal carcinoma.